ArticleInfection and immunity2003
Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome.International journal of molecular sciences · 2026Article
- An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndrome.iScience · 2025Article
- Article
- Therapeutic Uses of Bacterial Subunit Toxins.Toxins · 2021Review
- Molecular Biology ofToxins · 2020Review
- The structure of the Shiga toxin 2a A-subunit dictates the interactions of the toxin with blood components.Cellular microbiology · 2019Article
- Soluble Toll-Like Receptor 4 Impairs the Interaction of Shiga Toxin 2a with Human Serum Amyloid P Component.Toxins · 2018Article
- Structural Basis for the Specific Neutralization of Stx2a with a Camelid Single Domain Antibody Fragment.Toxins · 2018Article
- The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.Frontiers in immunology · 2018Review
- Mass Spectrometry-Based Method of Detecting and Distinguishing Type 1 and Type 2 Shiga-Like Toxins in Human Serum.Toxins · 2015Article
- A rapid and sensitive method to measure the functional activity of Shiga toxins in human serum.Toxins · 2015Article
- Article
- Glycolipid binding preferences of Shiga toxin variants.PloS one · 2014Article
- Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.Infection and immunity · 2013Article
- The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety?Toxins · 2012Review
- Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2.PloS one · 2011Article
- Article
- In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid-phase binding, competitive binding, and cytotoxicity neutralization assays indicate that the B pentamer and A subunit both contribute to human serum amyloid P (HuSAP) component binding to Stx2. A polyvalent globotriaosyl-ceramide receptor analog, Daisy, did not competitively inhibit HuSAP binding, implying that the two ligands bind to different Stx2 domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.